VNRX - VolitionRx Limited

NYSE American - Nasdaq Real Time Price. Currency in USD
5.23
-0.27 (-4.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close5.50
Open5.50
Bid0.00 x 1000
Ask5.26 x 1400
Day's Range5.10 - 5.61
52 Week Range1.67 - 6.84
Volume188,673
Avg. Volume221,738
Market Cap211.774M
Beta (3Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

    AUSTIN, Texas, Nov. 12, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2019. Volition management will host a conference call tomorrow, November 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Cameron Reynolds, President and Chief Executive Officer of Volition, upon releasing these results, commented, "I could not be more proud of our dedicated team at Volition, and the ground-breaking work we are doing.

  • PR Newswire

    VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

    Conference call to take place Wednesday, November 13, 2019 at 8:30 am Eastern time AUSTIN, Texas , Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) ("Volition") today announced ...

  • PR Newswire

    Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video

    AUSTIN, Texas, Oct. 29, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further $500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its subsidiary Volition Veterinary Diagnostics Development, LLC. On Friday, October 25, Volition announced the signing of multiple agreements to collaborate with Texas A&M University ("Texas A&M"), a leading U.S. institution to develop Nu.QTM Vet products.

  • PR Newswire

    Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC

    "The Texas A&M College of Veterinary Medicine & Biomedical Sciences is excited to be working with Volition to develop tests for the early detection of cancer and other diseases in animals," said Dr. Eleanor M. Green, the Carl B. King Dean of Veterinary Medicine at Texas A&M. "The research and clinical trials conducted by CVM's veterinary oncologists work on the cutting-edge of medicine and have benefitted both humans and animals.

  • PR Newswire

    Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

    AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department will be presenting at the Veterinary Cancer Society ("VCS") Annual Conference in Houston taking place this weekend. The VCS Conference is one of the largest veterinary oncology meetings in the world with presentations from keynote speakers, basic science and clinical science abstracts and poster sessions, in addition to technician workshops. Dr. Wilson-Robles commented: "I am delighted to have the opportunity to introduce the potential use of the Nu.Q(TM) technology to the veterinary oncology community at this prestigious event.

  • PR Newswire

    Volition Appoints Dr. Phillip Barnes to Board of Directors

    AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effective October 9, 2019. Dr. Barnes was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. As a non-executive member of the Company's Board, Dr. Barnes will provide independent expertise and strategic counsel to VolitionRx in connection with the planned commercialization of its Nu.QTM blood-based diagnostic platform.

  • PR Newswire

    Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

    AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could be used in two ways, firstly to increase specificity in Volition's current assays by removing the background signal and secondly, as an enabling technology in sequencing-based liquid biopsies by enriching nucleosomes of cancer origin from the blood. Dr. Mark Eccleston, one of the founding Scientists and the Business Development Director at Volition commented, "I am extremely excited that this enabling technology could bridge the gap between Volition's epigenetic profiling approach to early detection and those sequencing approaches that have so far been limited to personalized treatment selection.

  • ACCESSWIRE

    VolitionRX Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / VolitionRX Ltd. (NYSE: VNRX ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, 2019 at 8:30 AM Eastern ...

  • PR Newswire

    VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update

    AUSTIN, Texas, Aug. 12, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2019. Volition management will host a conference call tomorrow, August 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Click here to view an interview with Volition's Chief Executive Officer.

  • PR Newswire

    Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

    AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expert Nathan Dewsbury as its Chief Executive Officer.  A video regarding this announcement can be viewed here. "It was important to form a U.S. based Volition Veterinary subsidiary to enable dedicated focus on the development and commercialization of our Nu.QTM Vet products and help drive product development and early revenue for the company," commented Cameron Reynolds, President and Chief Executive Officer of Volition. Mr. Dewsbury has global expertise in the animal health industry having direct involvement in national testing programs, current health diagnostics platforms and commercializing next generation diagnostics.

  • PR Newswire

    VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

    Conference call to take place Tuesday, August 13, 2019 at 8:30 am Eastern time AUSTIN, Texas , Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...

  • PR Newswire

    Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

    Volition intends to use the net proceeds from this warrant exercise for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes. The shares of common stock issued upon exercise of the warrant were offered to an accredited investor in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations promulgated thereunder.

  • PR Newswire

    VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

    AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer.

  • PR Newswire

    VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

    AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, Belgium.  To date, Agencies from the Region have awarded Volition an aggregate of approximately $6 million in non-dilutive funding including this most recent award. "It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favourable terms to support the Company's continued development," commented Cameron Reynolds, President and Chief Executive Officer of Volition. Dr. Gaetan Michel, Chief Executive Officer of Volition's subsidiary, Belgian Volition SPRL, commented "We are delighted with the financial assistance that we have received from the Walloon Region and would like to thank Monsieur Pierre-Yves Jeholet, the Walloon Minister for Economy for his continued support.

  • PR Newswire

    VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

    AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2019. Volition management will host a conference call tomorrow, May 9, at 8:30 a.m. U.S. Eastern Time to discuss these results. Mr. Reynolds further commented "We were very happy to report the initial data from the first of our product grade assays during this first quarter.

  • PR Newswire

    VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

    AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer. Professor Chen Jin-Shing commented: "Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.

  • PR Newswire

    VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

    Conference call to take place Thursday, May 9, 2019 at 8:30 am Eastern time AUSTIN, Texas , May  6 , 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference ...

  • PR Newswire

    VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

    ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. "It has been a busy quarter with the public announcement of a number of initiatives and we were delighted to have the opportunity to discuss our plans at the Capital Markets Day event today," commented Chief Executive Officer, Cameron Reynolds. Following recently announced preliminary results from two proof of concept studies in lung cancer, Volition has signed a Memorandum of Understanding with the prestigious National Taiwan University through its wholly-owned subsidiary, Belgian Volition SPRL ("Belgian Volition"), to conduct a large-scale lung cancer study.

  • PR Newswire

    VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

    ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.  Any such relationship is subject to the negotiation of terms and conditions and the entry into a final binding agreement.  The MOU contemplates that Belgian Volition would form a new subsidiary in the United States to focus on the veterinary diagnostic market utilizing its NucleosomicsTM technology ("Vetco") and Texas A&M University would collaborate on the research and development of veterinary diagnostic products and is interested in negotiating a shareholding in Vetco.

  • PR Newswire

    VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

    ISNES, Belgium, April 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer. Professor Chen Jin-Shing commented: "The early data of the Nu.QTM technology platform is promising but clearly larger scale studies are required. Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.

  • PR Newswire

    VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

    ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering into a binding agreement to help facilitate the entrance of the Nu.QTM platform into China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, particularly in lung cancer, subject to reaching agreement on the terms and conditions of the proposed relationship, the parties intend to conduct three clinical studies in China in colorectal cancer, lung cancer and ovarian cancer.

  • PR Newswire

    VolitionRx Limited to Present at Conferences in March & April 2019

    ISNES, Belgium , March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell , is ...

  • PR Newswire

    VolitionRx Limited to Present at Conferences in the U.S. Next Week

    ISNES, Belgium, March 15, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr. Cameron Reynolds, is scheduled to present at two conferences in the U.S. next week. During the conferences, Mr. Reynolds will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced clinical data and upcoming 2019 milestones.

  • PR Newswire

    VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update

    ISNES, Belgium, March 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year ended December 31, 2018. Volition management will host a conference call tomorrow, March 14, at 8:30a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.